Opinion Volume 3 Issue 5
Cedars - Jebel Ali International Hospital, UAE
Correspondence: Hajj Adel Anis, Medical Oncologist at Cedars - Jebel Ali International Hospital, 9370 Rue Lajeunesse, Montreal, UAE, Tel 438-992-5516
Received: October 25, 2015 | Published: December 7, 2015
Citation: Anis HA. Introduction to cancer immunotherapy. J Cancer Prev Curr Res. 2015;3(5):358-359. DOI: 10.15406/jcpcr.2015.03.00097
Cancer immunotherapy represents the most promising new cancer treatment modality since the development of the first chemotherapies in the late 1940s.
Immunotherapy is a treatment that uses certain aspects of a person’s immune system to struggle against diseases such as cancer. This can be done in two different ways:
Some types of immunotherapy are also sometimes called biologic therapy. In the last few decades immunotherapy has become an important item in the treatment of some types of cancer. The immune system is a set of organs, special cells and substances that help protect from infections and some other diseases. Immune cells and the substances circulate through the body to protect it from germs that cause infections. The immune system keeps control of all of the materials normally found in the body. Any new one that the immune system doesn’t recognize raises an alarm, driving the immune system to attack it. The immune response can destroy anything containing the foreign substance, such as germs or cancer cells. However, the immune system has a more difficult time targeting cancer cells. This is because cancer starts when cells become altered and start to grow out of control. The immune system doesn’t always recognize cancer cells as foreign. Cancer cells themselves can also give off substances that keep the immune system in check. Clearly, there are limits on the immune system’s ability to fight cancer on its own. To overcome this, researchers have found ways to help the immune system recognize cancer cells and strengthen its response so that it will destroy them. The main types of immunotherapy now being used to treat cancer include:
One way the immune system attacks foreign substances in the body is by making large numbers of antibodies. Researchers can design antibodies that specifically target a certain antigen, such as one found on cancer cells. These are known as monoclonal antibodies. To make a monoclonal antibody, researchers first have to identify the right antigen to attack. Different types of monoclonal antibodies are used in cancer treatment.
An important part of the immune system is its ability to tell between normal cells in the body and those it sees as foreign. This lets the immune system attack the foreign cells while leaving the normal cells alone. To do this, it uses checkpoints -molecules on certain immune cells that need to be activated (or inactivated) to start an immune response. Cancer cells sometimes find ways to use these checkpoints to avoid being attacked by the immune system. But drugs that target these checkpoints hold a lot of promise as cancer treatments.
We all know about vaccines given to healthy people to help prevent infections. Most cancer vaccines work the same way, but they make the person’s immune system attack cancer cells. The goal is to help treat cancer or to help keep it from coming back after other treatments. But there are also some vaccines that may actually help prevent certain cancers.
Non-specific immunotherapies don’t target cancer cells specifically. They stimulate the immune system in a more general way, but this can still sometimes lead to a better immune response against cancer cells. These are essentially cytokines. Cytokines are chemicals made by some immune system cells. They are crucial in controlling the growth and activity of other immune system cells and blood cells. Cytokines are injected, either under the skin, into a muscle or into a vein. The problem we face, however, is that immunoselection continually occurs during tumor development with the malignant tumors that eventually emerge in patients often being resistant to elimination by the immune system. The challenge for researchers in the future is identifying patients for which immunotherapy will be efficacious and to conceive means of reactivating the immune response against tumors.
None.
The authors declare that there is no conflict of interest.
©2015 Anis. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.